Hosted on MSN15d
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio
Dr. Reddy’s enjoys a strong position in the generics market. As of Sept. 30, 2024, cumulatively, 80 generic filings were pending approval from the FDA (75 abbreviated new drug applications ...
Deccan Chronicle14d
Dr P.V. Nanda Kumar Reddy Appointed as Kaloji Varsity VC
Dr. P.V. Nanda Kumar Reddy has been appointed as the new vice-chancellor of Kaloji Narayana Rao University of Health Sciences ...
Drug Store News12d
FDA accepts BLA submission from Dr. Reddy's, Alvotech for proposed Prolia, Xgeva biosimilars
After approval by the FDA, AVT03 is expected to be supplied in a single-dose prefilled syringe containing 60 mg in a 1 ml ...
Dr. P.V. Nanda Kumar Reddy appointed as vice-chancellor of KNRUHS
Dr. P.V. Nanda Kumar Reddy appointed as new Vice-Chancellor of KNRUHS in Telangana after legal scrutiny over predecessor's tenure.
Corient Private Wealth LLC Grows Stock Holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY)
Corient Private Wealth LLC grew its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) by 447.3% in the ...